Evidence map›Paper›PMID 38340174›Full record

ReviewInternational ophthalmology2024

The application of high-throughput sequencing technology in corneal diseases.

Jing Yi Zhao, Yu Xi He, Mei Liang Wu, Rui Qing Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jing Yi Zhao *The Second Clinical Medical College of Jilin University, Changchun, 130012, Jilin, China.
Yu Xi He *The Eye Center, The Second Hospital of Jilin University, Changchun, 130041, Jilin, China.
Mei Liang WuThe Eye Center, The Second Hospital of Jilin University, Changchun, 130041, Jilin, China.
Rui Qing WangThe Eye Center, The Second Hospital of Jilin University, Changchun, 130041, Jilin, China. wrq@jlu.edu.cn.

Funding

Jilin Province Health Science and technology capacity promotion project ZYXWST2021010
6 · The paper itself

Abstract

High-throughput sequencing technology, also known as next-generation sequencing technology, can explore new biomarkers and specific gene mutations. It has a pivotal role in promoting the gene research, which can limit the detection area, lessen the time needed for sequencing. Also, it can quickly screen out the suspected pathogenic genes of patients, gain the necessary genetic data, and provide the basis for clinical diagnosis and genetic counseling. In the research of corneal diseases, through the DNA sequencing of patients' diseased cells, it can provide a deeper understanding of corneal diseases and improve the diagnosis, classification and treatment alternatives of various corneal diseases. This article will introduce the application progress of high-throughput sequencing technology in corneal diseases, which will help to understand the application of this technology in various corneal diseases.

Indexed as

High-Throughput Nucleotide SequencingHumansMutationSequence Analysis, DNAAdjuvant therapyCorneal diseasesDisease diagnosisHigh-throughput sequencing

Identifiers

PMID38340174
PMCPMC10858842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.